x

Coronavirus

Serbia to Purchase of 2 Million Additional Doses of China’s COVID-19 Vaccine

BELGRADE, Serbia — Serbia has signed a deal with China for the purchase of 2 million additional doses of the Sinopharm COVID-19 vaccine, which already has helped the Balkan country rapidly vaccinate its population.

Serbian President Aleksandar Vucic signed the contract on Thursday. He thanked Chinese President Xi Jinping, the Chinese Communist Party leadership and Sinopharm's management “for supplying the vaccines at these difficult times.”

Vucic has often criticized the European Union and the West for the slow delivery of COIVD-19 vaccines to Serbia and other less developed nations and praised China and Russia for coming to the rescue.

Serbia, which formally seeks EU membership, has announced plans to start the production of vaccines developed in China and Russia that have not yet been approved by the European Medicines Agency for use.

The Balkan nation of 7 million has administered more than 2 million doses so far, one of the highest rates in Europe. Most Serb citizens have received the Sinopharm vaccines, followed by Sputnik V, Pfizer and AstraZeneca jabs.

RELATED

BEIJING (AP) — Genetic material collected at a Chinese market near where the first human cases of COVID-19 were identified show raccoon dog DNA comingled with the virus, adding evidence to the theory that the virus originated from animals, not from a lab, international experts say.

Top Stories

Columnists

A pregnant woman was driving in the HOV lane near Dallas.

General News

FALMOUTH, MA – The police in Falmouth have identified the victim in an accident involving a car plunging into the ocean on February 20, NBC10 Boston reported.

General News

NEW YORK – Meropi Kyriacou, the new Principal of The Cathedral School in Manhattan, was honored as The National Herald’s Educator of the Year.

Video

Enter your email address to subscribe

Provide your email address to subscribe. For e.g. [email protected]

You may unsubscribe at any time using the link in our newsletter.